Tecarfarin, a novel therapy designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with End Stage Renal Disease and Atrial Fibrillation, may be a new treatment option for this underserved patient population PONTE VEDRA,...
Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population
read more